<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655560</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02286</org_study_id>
    <nct_id>NCT04655560</nct_id>
  </id_info>
  <brief_title>Understanding Barriers and Facilitators to the Participation of Women Living With HIV in Clinical Trials : a Mixed-method Study (EVA)</brief_title>
  <acronym>EVA</acronym>
  <official_title>Understanding Barriers and Facilitators to the Participation of Women Living With HIV in Clinical Trials : a Mixed-method Study (EVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the most important barriers and facilitators to the participation of cisgender&#xD;
      women living with HIV in clinical trials (perceived and real) and to establish possible&#xD;
      mechanisms leading to refusal of trial participation. Specifically, psychosocial factors&#xD;
      and/or cultural environments that enhance or undermine HIV-positive cisgender women's&#xD;
      participation. These can include social inclusion, confidence in research, perceived personal&#xD;
      vulnerability, cultural, familial and professional environment.&#xD;
&#xD;
      The investigators expect to propose pragmatic solutions to enhance participation of&#xD;
      HIV-positive cisgender women in clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of barriers and facilitators to the participation of women in clinical trials (HIV) through a questionnaire</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Specific questions will be asked during a face-to-face interview to identify factors favoring or barriers to the participation of women in clinical trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of mechanisms leading to refusal of trial participation through a questionnaire</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Specific questions will be asked during a face-to-face interview to understand mechanisms leading to refusal of trial participation.&#xD;
Specifically, psychosocial factors and/or cultural environments that enhance or undermine HIV-positive cisgender women's participation. These can include social inclusion, confidence in research, perceived personal vulnerability, cultural, familial and professional environment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Offering solutions for a better inclusion of HIV-women in clinical trials - qualitative study</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Analysis of questionnaires allowing recommendations to be made</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Women living with HIV</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>qualitative study</description>
    <arm_group_label>Women living with HIV</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women living with HIV&#xD;
&#xD;
        Note: ethnicity will not represent a selection's criteria. However, special care will be&#xD;
        payed to assure a certain heterogeneity in the sample concerning this aspect.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cisgender women&#xD;
&#xD;
          -  Adult (&gt;18 years) HIV-infected&#xD;
&#xD;
          -  Informed consent documented by signature&#xD;
&#xD;
          -  Patients under stable antiretroviral therapy&#xD;
&#xD;
          -  French speaking (sufficient fluency for a conversation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having participated in a previous qualitative study about Cure Trials acceptability&#xD;
             among HIV patients&#xD;
&#xD;
          -  Incapable of discernment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Calmy Alexandra</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Clinical trials</keyword>
  <keyword>Women</keyword>
  <keyword>qualitative study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

